A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.

Journal article

The immunogenicities of candidate DNA- and modified vaccinia virus Ankara (MVA)-vectored human immunodeficiency virus (HIV) vaccines were evaluated on their own and in a prime-boost regimen in phase I clinical trials in healthy uninfected individuals in the United Kingdom. Given the current lack of approaches capable of inducing broad HIV-neutralizing antibodies, the pTHr.HIVA DNA and MVA.HIVA vaccines focus solely on the induction of cell-mediated immunity. The vaccines expressed a common im...

Expand abstract

Authors: Mwau, M; Cebere, I; Sutton, J; Chikoti, P; Winstone, N

• Publication status: Published
• Journal: Journal of general virology
• Volume: 85
• Issue: Pt 4
• Pages: 911-919
• Publication date: 2004-04-01
• DOI: 10.1099/vir.0.19701-0
• EISSN: 1465-2099
• ISSN: 0022-1317
• Language: English
• Keywords: Adolescent; Vaccinia virus; gag Gene Products, Human Immunodeficiency Virus; Vaccines, DNA; Humans; HIV Antigens; Injections, Intramuscular; Adult; Immunization, Secondary; Viral Proteins; Female; Gene Products, gag; Male; Injections, Intradermal; HIV Core Protein p24; AIDS Vaccines; Safety; T-Lymphocytes; Vaccines, Synthetic; HIV Antibodies; Middle Aged; HIV-1